The Russian Competition Authority investigates whether a pharmaceutical company with dominant position in wholesale of certain generics unreasonably refused to conclude contract for medicine supply (Ipsen / Biotek)

FAS Russia: Ipsen Unreasonably Refused Biotek to Conclude Contract for Medicine Supply* In order not to enter into a contract with a counterparty the pharmaceutical company has repeatedly changed its commercial policy during the review of the distributor's application. The FAS Russia issued a warning to the pharmaceutical company Ipsen to stop actions that contain signs of violation of the Law on Protection of Competition. Thus, having no economic and technological

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

Quotation

Russian Competition Authority, The Russian Competition Authority investigates whether a pharmaceutical company with dominant position in wholesale of certain generics unreasonably refused to conclude contract for medicine supply (Ipsen / Biotek), 5 October 2020, e-Competitions November 2020 - II, Art. N° 97190

Visites 123

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues